GSK says it will invest in expanding three manufacturing facilities
Pharmaceuticals giant GSK has announced it is investing 拢275m in expanding three of its manufacturing facilities.
The money will be invested in sites at Barnard Castle, Durham; Montrose, Scotland; and Ware, Hertfordshire.
Investment will be used to boost production of GSK鈥檚 latest respiratory and large molecule biological medicines, the vast majority of which will be for export to global markets.
Andrew Witty, chief executive of GSK, said: 鈥淚t is testament to our skilled UK workforce and the country鈥檚 leading position in life sciences that we are making these investments in advanced manufacturing here.鈥�
GSK鈥檚 investment plans
- Barnard Castle in County Durham is one of GSK鈥檚 biggest secondary manufacturing sites, employing 1,100 people. The site supplies nearly half a million packs of products per day to 140 global markets. The investment announced today of 拢92 million will fund the construction of an aseptic sterile facility supporting the manufacture of existing and new biopharmaceutical assets in our pipeline.
- Montrose in Angus in Scotland manufactures active ingredients for respiratory, HIV and vaccine products and employs over 450 staff. This investment of approximately 拢110 million will provide a new, state-of-the-art facility for the manufacture of respiratory active ingredients.
- Ware in Hertfordshire, employs 1200 staff, manufacturing innovative respiratory products. Today鈥檚 investment of 拢74 million will support further expansion of the company鈥檚 new Ellipta respiratory inhaler through additional manufacturing capacity at the site.
No comments yet